Now that LLY won the bidding war from BMY over Imclone for Erbitux how does that change the dynamics of LLY to RGDX relationship? If this stool test is nescessary to initiate erbitux treatment might not LLY even want to own RGDX to assure compliance and drive sales? Seems to me to be a good fit..sell the kit to the onc office on the same sales call for erbitux. I can see at least a joint effort or some sort of a co-marketing agreement....any news on this?